Cassava Sciences Inc SAVA

Cassava Sciences, Inc. is a clinical-stage biotechnology company that develops drugs for neurodegenerative diseases. Formerly known as Pain Therapeutics, Inc., the company changed its name to Cassava Sciences, Inc. in March 2019. Founded in 1998 by Remi Barbier and Barry M. Sherman, Cassava Sciences, Inc. has headquarters in Austin, Texas.

The company’s leading therapeutic product candidate is Simufilam, a small molecule drug that has been designed to stabilise a critical protein in the brain as a treatment for Alzheimer's disease. The company also has a blood-based diagnostic test known as SavaDx, which has been developed to detect Alzheimer's disease. Both Simufilam and SavaDx are currently undergoing extensive clinical trials throughout the US and Canada.

The company's research programs receive financial and scientific support from the National Institutes of Health (NIH), with approximately $20 million awarded between 2013 and 2021. The company had no product revenues between that period, and was purely focused on research and development, with just 25 employees. Stock for Cassava Sciences, Inc. is listed on the NASDAQ CM stock exchange under the ticker SAVA. The company’s stock has been listed on this exchange since August 2000.

Stay up to date on SAVA share price movements by adding it to your eToro watchlist.